204 related articles for article (PubMed ID: 29299356)
1. Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm.
Clasen SC; Ky B; O'Quinn R; Giantonio B; Teitelbaum U; Carver JR
J Gastrointest Oncol; 2017 Dec; 8(6):970-979. PubMed ID: 29299356
[TBL] [Abstract][Full Text] [Related]
2. Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.
Chakrabarti S; Sara J; Lobo R; Eiring R; Finnes H; Mitchell J; Hartgers M; Okano A; Halfdanarson T; Grothey A
Clin Colorectal Cancer; 2019 Mar; 18(1):52-57. PubMed ID: 30396850
[TBL] [Abstract][Full Text] [Related]
3. A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicity.
Kasi A; Gaudel P; Lekkala M; Al-Rajabi R; Saeed A; Sun W; Porter C
J Oncol Pharm Pract; 2023 Dec; 29(8):1951-1956. PubMed ID: 36883259
[TBL] [Abstract][Full Text] [Related]
4. Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge.
Vater LB; Lefebvre B; Turk A; Clasen SC
Curr Oncol Rep; 2022 Jul; 24(7):943-950. PubMed ID: 35347593
[TBL] [Abstract][Full Text] [Related]
5. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.
Osterlund P; Kinos S; Pfeiffer P; Salminen T; Kwakman JJM; Frödin JE; Shah CH; Sorbye H; Ristamäki R; Halonen P; Soveri LM; Heervä E; Ålgars A; Bärlund M; Hagman H; McDermott R; O'Reilly M; Röckert R; Liposits G; Kallio R; Flygare P; Teske AJ; van Werkhoven E; Punt CJA; Glimelius B
ESMO Open; 2022 Jun; 7(3):100427. PubMed ID: 35798468
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm.
Zafar A; Drobni ZD; Lei M; Gongora CA; Quinaglia T; Lou UY; Mosarla R; Murphy SP; Jones-O'Connor M; Mahmood A; Hartmann S; Gilman HK; Weekes CD; Nipp R; Clark JR; Clark JW; Blaszkowsky LS; Tavares E; Neilan TG
PLoS One; 2022; 17(4):e0265767. PubMed ID: 35390017
[TBL] [Abstract][Full Text] [Related]
7. The Role of Vasospasm and Microcirculatory Dysfunction in Fluoropyrimidine-Induced Ischemic Heart Disease.
Fabin N; Bergami M; Cenko E; Bugiardini R; Manfrini O
J Clin Med; 2022 Feb; 11(5):. PubMed ID: 35268333
[TBL] [Abstract][Full Text] [Related]
8. Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vasospasm during first 5-FU infusion.
Redman JM; Rhea LP; Brofferio A; Whelpley M; Gulley JL; Gatti-Mays ME; McMahon S; Cordes LM; Strauss J
J Gastrointest Oncol; 2019 Oct; 10(5):1010-1014. PubMed ID: 31602339
[TBL] [Abstract][Full Text] [Related]
9. 5-Fluorouracil Rechallenge After Cardiotoxicity.
Desai A; Mohammed T; Patel KN; Almnajam M; Kim AS
Am J Case Rep; 2020 Aug; 21():e924446. PubMed ID: 32860674
[TBL] [Abstract][Full Text] [Related]
10. Oral versus intravenous fluoropyrimidines for colorectal cancer.
Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
[TBL] [Abstract][Full Text] [Related]
11. Fluoropyrimidine-Associated Cardiotoxicity.
Kanduri J; More LA; Godishala A; Asnani A
Cardiol Clin; 2019 Nov; 37(4):399-405. PubMed ID: 31587781
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
13. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.
Layoun ME; Wickramasinghe CD; Peralta MV; Yang EH
Curr Oncol Rep; 2016 Jun; 18(6):35. PubMed ID: 27113369
[TBL] [Abstract][Full Text] [Related]
14. Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study.
Raber I; Warack S; Kanduri J; Pribish A; Godishala A; Abovich A; Orbite A; Dommaraju S; Frazer M; Peters ML; Asnani A
Oncologist; 2020 Mar; 25(3):e606-e609. PubMed ID: 32162823
[TBL] [Abstract][Full Text] [Related]
15. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
16. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
Ransom D; Wilson K; Fournier M; Simes RJ; Gebski V; Yip D; Tebbutt N; Karapetis CS; Ferry D; Gordon S; Price TJ
Ann Oncol; 2014 Jan; 25(1):117-21. PubMed ID: 24299960
[TBL] [Abstract][Full Text] [Related]
17. Role of ABC transporters in fluoropyrimidine-based chemotherapy response.
Nies AT; Magdy T; Schwab M; Zanger UM
Adv Cancer Res; 2015; 125():217-43. PubMed ID: 25640272
[TBL] [Abstract][Full Text] [Related]
18. Cardiac toxicity with capecitabine, vinorelbine and trastuzumab therapy: case report and review of fluoropyrimidine-related cardiotoxicity.
Le Brun-Ly V; Martin J; Venat-Bouvet L; Darodes N; Labourey JL; Genet D; Tubiana-Mathieu N
Oncology; 2009; 76(5):322-5. PubMed ID: 19307737
[TBL] [Abstract][Full Text] [Related]
19. Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report.
Akpek G; Hartshorn KL
Cancer Chemother Pharmacol; 1999; 43(2):157-61. PubMed ID: 9923822
[TBL] [Abstract][Full Text] [Related]
20. Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.
Manfredi S; Turpin A; Malka D; Barbier E; Laurent-Puig P; Zaanan A; Dahan L; Lièvre A; Phelip JM; Michel P; Hautefeuille V; Legoux JL; Lepage C; Tougeron D; Aparicio T
Dig Liver Dis; 2020 Oct; 52(10):1143-1147. PubMed ID: 32747302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]